KATE, Japan's No. 1 Makeup Brand, Launches Strategic Initiatives to Strengthen Business and Brand Recognition Across Asia
Article content
TOKYO — Kao Corporation (TOKYO:4452) has identified its international makeup brand KATE as a strategic growth driver within its cosmetics portfolio. This initiative aligns with the company's ambition to establish a 'Global Sharp Top' business framework. In line with this vision, Kao is making significant investments to amplify KATE 's global presence.
Article content
As part of this initiative, KATE will broaden the reach of its signature 'Shadow Enhancing Makeup' philosophy—a technique deeply inspired by Japan's cultural appreciation for shadows and light. In its role as Japan's No.1 makeup brand *1, KATE will also collaborate with iconic Japanese cultural content to showcase the richness of both Japanese makeup culture and the broader essence of Japanese heritage on the global stage.
Article content
To enhance the brand's value, KATE will elevate the experience at its global flagship store KATE TOKYO Shibuya Sakura Stage, through immersive UX experiences. This strategic move aims to accelerate global growth, particularly across Asia.
Article content
Brand Expansion Strategy in Asia
Article content
Since its launch in 1997, KATE has championed the slogan 'NO MORE RULES.' empowering individuals to express their personality and confidence through makeup, unbound by trends or convention. Recognized for pioneering the shadow enhancing makeup technique, KATE creates striking facial dimension and expression through the interplay of light and shadow.
Article content
*1
Article content
and has played a significant role in evolving Japanese makeup culture. The brand is now expanding its signature makeup technique to consumers across Asia, where makeup culture shares many similarities with Japan, and where eye makeup plays a pivotal role. As a distinguished ambassador of Japanese makeup culture, the brand aims to transcend borders while continuing to inspire individuality and confidence in its consumers.
Article content
*1 Survey by INTAGE SRI+: Cumulative sales amount in the makeup market from January 2021 to December 2024
Article content
June: Collaboration with Popular Anime 'JUJUTSU KAISEN Hidden Inventory / Premature Death' *2
Article content
Beginning June 2, KATE is excited to unveil a limited-edition collaboration with the globally acclaimed comic-turned anime series JUJUTSU KAISEN. Known for its commitment to breaking conventions and fostering creative self-expression through meticulously designed products, KATE aims to inspire users to unleash their creativity. This collaboration introduces a collection of limited-edition products featuring packaging designs inspired by striking scenes that highlight the intense gaze of the iconic character Satoru Gojo. The collection will be available from June 21.
Article content
Under the campaign slogan 'Makeup is the most powerful spell to control your confidence', the collaboration highlights the transformative potential and creative possibilities of makeup on a global scale. To support the campaign, a dedicated photo spot featuring Satoru Gojo will be installed at the brand's flagship store, KATE TOKYO Shibuya Sakura Stage. Additionally, a special microsite will be launched on KATE 's official website. The campaign will leverage a comprehensive 'OMO (Online Merges with Offline)' strategy, seamlessly integrating social media platforms such as X, Instagram, and TikTok with in-store experiences and campaign video content, maximizing user interaction and engagement.
Article content
Limited-Edition JUJUTSU KAISEN Collaboration Product Lineup
Article content
*2 © Gege Akutami / Shueisha, JUJUTSU KAISEN Project
Article content
In July, KATE is set to launch a collaboration with renowned Japanese artists popular throughout Asia. Centered on the theme 'Shadow Enhancing Makeup Transcends Dimensions', this campaign illustrates how the expert application of highlights and shadows can evoke stunning beauty that bridges the two- and three-dimensional realms.
Article content
In addition to product offerings, including eyeshadow and eyebrow items designed for shading techniques, the campaign will symbolically portray the process of unlocking one's individuality and gaining confidence through hyper-realistic visual techniques. Local brand ambassadors will be appointed in key Asian markets such as Taiwan and Thailand to amplify the cultural narrative and reach of Japanese makeup artistry.
Article content
September: Jointly developed with Universal Studios Japan, a next-generation walkthrough attraction
Article content
On September 5, KATE will unveil a collaboration with Universal Studios Japan, a popular destination for both local and international visitors. Together, they will co-create a new attraction:
'Witches of House 18: Bewitching Mansion of Emotion', as part of the park's Halloween Horror Nights event.
Article content
This marks the first-ever co-development of an attraction between Universal Studios Japan and an official event partner. Centered on the theme 'Unleash the self hidden inside you', the experience draws out a wide range of emotions through the guidance of four witches, revealing new dimensions of the self. This collaboration between KATE and Universal Studios Japan delivers a one-of-a-kind experience, unlocking extraordinary surprises and creative freedom that empower guests to express their best selves.
Article content
KATE
Article content
will continue to promote Japanese makeup culture throughout Asia by engaging in ongoing media outreach and creating unique consumer experiences. With the goal of becoming Asia's No.1 makeup brand, Kao is dedicated to enhancing
Article content
'
Article content
cosmetics portfolio.
Article content
Related Information
Article content
KATE Official Brand Website
Article content
Article content
KATE unveils first global flagship store (Press release from July 2024)
Article content
Article content
JUJUTSU KAISEN Official TV Anime Website
Article content
Article content
Universal Studios Japan Official Website
Article content
Article content
KATE
Article content
is the official event partner of Universal Studios Japan.
Article content
HARRY POTTER and all related characters and elements © & ™ Warner Bros. Entertainment Inc. Publishing Rights © J.K. Rowling.
MINIONS TM & © 2025 Universal Studios.
© Nintendo
TM & © Universal Studios & Amblin Entertainment
TM & © 2025 Universal Studios. All rights reserved. CR25-1897
Article content
About Kao
Article content
Kao, a Japan-based manufacturer of personal care and household products, cosmetics, and specialty chemicals creates high-value-added products and services that provide care and enrichment for the life of all people and the planet. Through its brands such as Attack laundry detergent, Bioré and Jergens skin care products, Laurier sanitary products, Curél, SENSAI, and MOLTON BROWN cosmetics, and Oribe hair care products, Kao is part of the everyday lives of people across Asia, the Americas, Europe, the Middle East, and Africa. Combined with its chemical business, which contributes to a wide range of industries, Kao generates about 1,630 billion yen in annual sales. Kao employs about 32,600 people worldwide and has more than 130 years of history in innovation. As an enterprise that provides products people use on a daily basis, the Kao Group takes responsibility to actively reduce the environmental footprint of its products throughout the product lifecycle. This is laid out in Kao's ESG strategy, the Kirei Lifestyle Plan, which launched in 2019.
Please visit the Kao Group website for additional information.
Article content
Article content
Article content
Article content
Contacts
Article content
Media inquiries should be directed to:
Article content
Article content
Public Relations
Article content
Article content
Article content
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
2 hours ago
- Globe and Mail
'Largest of its Kind' Tesla Stock (NASDAQ:TSLA) Notches Up With New Battery Power Plant in China
While most of us tend to focus on electric vehicle giant Tesla (TSLA) for, well, its electric vehicles, there is one part of Tesla that tends to go oddly underappreciated: its batteries. The things that make the cars go also have a great potential to keep the lights on at our homes. And they may be about to do just that in China, as Tesla will be building a new 'grid-scale battery power plant' therein. The news sent Tesla shares up fractionally in Friday afternoon's trading. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter The new plant that Tesla is looking to build represents something of a novel approach to wide-scale power generation. While more and more users are looking to renewables like wind and solar for some part of grid-power operations, even the most fervent supporters of same know that there is a problem there: the sun does not always shine, nor does the wind always blow. So battery plants are being considered more and more as a way to store energy in the good times, to be parceled out to the grid later on. And with Tesla's battery factory in Shanghai already having produced 100 Megapacks—the kind of battery that works at grid-level—in the first quarter alone, Tesla might be able to set up such a plant fairly rapidly. It will be quite a plant, too; reports note that the project will be '…the largest grid-side energy storage project in China,' Tesla representatives noted. Given that one Megapack can offer one megawatt for four hours, that could indeed be a serious power project. Try Before You Buy Want to test-drive a Tesla? Well, you may have an opportunity to do just that thanks to a partnership effort between Tesla and the Electrify Expo, which will allow users to take a Tesla home for the weekend and put it through its paces before returning it. Tesla is just the first such company to go in right now, as Electrify Expo is looking to bring in more carmakers to the deal. Though right now, this is limited to the Los Angeles show only, which starts tomorrow, expansions are likely to follow. Dubbed the 'Electrify Weekender' experience, the event is likely to expand to Chicago, Dallas, New York, San Francisco and Seattle by the end of the year, with the Los Angeles experience serving as a way to work out any kinks in the program. Is Tesla a Buy, Hold or Sell? Turning to Wall Street, analysts have a Hold consensus rating on TSLA stock based on 14 Buys, 12 Holds, and nine Sells assigned in the past three months, as indicated by the graphic below. After a 75.97% rally in its share price over the past year, the average TSLA price target of $286.14 per share implies 11.93% downside risk. See more TSLA analyst ratings Disclosure
Globe and Mail
17 hours ago
- Globe and Mail
Ovarian Cancer Market Forecast to 2034: Advancing Treatment Frontiers and Epidemiological Shifts
Ovarian cancer remains a significant global health challenge, often diagnosed at an advanced stage due to non-specific symptoms and a lack of effective early screening. It encompasses a spectrum of histological subtypes, including high-grade serous (HGSOC), low-grade serous (LGSOC), and epithelial tumors, each with unique biological and clinical features. High recurrence rates and poor long-term survival continue to drive the urgent need for improved treatment options and earlier detection. DelveInsight's latest report, ' Ovarian Cancer – Market Insight, Epidemiology, and Market Forecast – 2034,' provides a comprehensive overview of the disease's burden across the US, EU4 (Germany, France, Italy, Spain), the UK, and Japan. It offers in-depth segmentation by subtype, stage, age group, and biomarker status, alongside historical and projected epidemiological trends. The analysis highlights rising incidence rates, shifting subtype proportions—particularly serous carcinomas—and the evolving landscape of diagnostic and therapeutic innovation. The ovarian cancer market has transformed in recent years, driven by the expanding use of PARP inhibitors, antiangiogenic agents, and emerging targeted therapies. These options have shifted the treatment paradigm, particularly for BRCA-mutated, HRD-positive, and platinum-sensitive disease. Nonetheless, persistent issues such as chemoresistance, limited options in late-line settings, and variability in biomarker testing are hindering further progress. Looking ahead, the market is anticipated to grow steadily through 2034, propelled by innovations in epigenetic modulators, antibody-drug conjugates (ADCs), immune-oncology combinations, and advanced diagnostics like liquid biopsies. Enhanced biomarker testing and personalized treatment strategies will support optimized patient care. DelveInsight's full report explores pipeline highlights, market drivers and barriers, and strategic recommendations for stakeholders aiming to transform the outlook for ovarian cancer patients. Request a sample and uncover the latest breakthroughs shaping the Ovarian Cancer market landscape and future outlook Some of the key insights of the Ovarian Cancer Market Report: • In 2024, the ovarian cancer market in the 7MM was valued at USD 2.7 billion. • Market size is expected to grow with the launch of new ovarian cancer therapies. • The U.S. held the largest share, reaching USD 1.92 billion in 2024. • Total incident ovarian cancer cases in the 7MM were 61K in 2024. • The U.S. reported the highest number of high and low-grade serous ovarian cancer cases. • There were approximately 37.6K serous ovarian cancer cases in the 7MM in 2024. • In January 2025, IPS HEART received Orphan Drug Designation (ODD) from the FDA for GIVI-MPCs, recognizing their potential to create new muscle with full-length dystrophin in Becker Muscular Dystrophy (BMD). The therapy has shown promising results in generating human muscle with full-length dystrophin in dystrophic pigs, young and aged Duchenne Muscular Dystrophy (DMD) mice, and an Ovarian Cancer mouse model. • In April 2025, Biocon Biologics received FDA approval for JOBEVNE (bevacizumab-nwgd), a biosimilar to Avastin®, for intravenous use. JOBEVNE is approved for multiple cancers, including metastatic colorectal cancer, non-squamous non-small cell lung cancer, recurrent glioblastoma, metastatic renal cell carcinoma, advanced cervical cancer, and ovarian, fallopian tube, or primary peritoneal cancer. • In February 2025, the FDA granted fast-track designation to CUSP06, a CDH6-directed antibody-drug conjugate (ADC), for the treatment of patients with platinum-resistant ovarian cancer. • Emerging therapies for ovarian cancer include Avutometinib + defactinib, Relacorilant, IMFINZI, Rinatabart sesutecan, Olvimulogene nanivacirepvec, Nemvaleukin alfa, Catequentinib, Raludotatug deruxtecan, Luveltamab Tazevibulin, Sacituzumab tirumotecan, Azenosertib (ZN-c3) + Niraparib, TORL-1-23, and others. • Key companies involved in the treatment of ovarian cancer include Genmab, AstraZeneca, On Target Laboratories, Chipscreen Biosciences, Aravive, Inc., Allarity Therapeutics, Merck KGaA, GlaxoSmithKline, Aprea Therapeutics, Verastem, Inc., Ellipses Pharma, Impact Therapeutics, Inc., BeiGene, Apexigen, Novartis Oncology, VBL Therapeutics, Cristal Therapeutics, Bayer, Regeneron Pharmaceuticals, DCPrime BV, AIM ImmunoTech Inc., Pharmicell Co., Ltd., Shattuck Labs, Inc., Laekna Limited, Celsion, and others. Curious to see the graphical version of these numbers? The ovarian cancer infographic is ready for you. Check it out here! Ovarian Cancer Overview Ovarian cancer is a complex and often late-diagnosed malignancy arising from the epithelial cells, stromal cells, or germ cells of the ovary. Among these, epithelial ovarian cancer is the most prevalent, accounting for over 90% of malignant ovarian tumors. Due to its subtle early symptoms and lack of reliable screening methods, the disease is frequently diagnosed at advanced stages, contributing to its high mortality rate among gynecological cancers. The most common and aggressive subtype is High-Grade Serous Ovarian Cancer (HGSOC), which often presents with widespread peritoneal metastases. In contrast, Low-Grade Serous Ovarian Cancer (LGSOC) tends to follow a more indolent course but shows resistance to standard chemotherapy, highlighting a critical unmet need for targeted therapies. Genetic mutations such as BRCA1/2 and alterations in the MAPK pathway (BRAF/KRAS/NRAS/NF1) and homologous recombination deficiency (HRD) status play a pivotal role in disease stratification and therapy selection. Over the past decade, the ovarian cancer treatment landscape has evolved with the introduction of PARP inhibitors, anti-angiogenic agents, and targeted therapies that have significantly improved outcomes in biomarker-driven subpopulations. Despite these advancements, resistance development, limited options for certain subtypes like LGSOC, and high relapse rates continue to challenge long-term disease control. As research progresses, efforts are focused on improving early diagnosis, personalizing treatment based on molecular profiling, and expanding therapeutic options through clinical trials and novel drug development. Get a free sample for the Ovarian Cancer market forecast, size & share analysis report: Ovarian Cancer Epidemiology The epidemiology section offers an overview of historical, current, and projected trends in the seven major countries (7MM) from 2020 to 2034. It helps identify the factors influencing these trends by examining various studies and perspectives from key opinion leaders. Additionally, the section provides an in-depth analysis of the diagnosed patient population and future trends. Ovarian Cancer Epidemiology Segmentation: The Ovarian Cancer market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM, segmented into: • Total incident cases of Ovarian Cancer • Age-specific cases of Ovarian Cancer • Type-Specific Cases of Ovarian Cancer • Stage-specific Cases of high and Low-Grade Serous Ovarian Cancer • Biomarker-specific Cases of high and Low-Grade Serous Ovarian Cancer Ovarian Cancer Drugs Uptake and Pipeline Development Activities The Drug Uptake section offers a detailed analysis of the adoption trends of newly launched and upcoming therapies for Ovarian Cancer throughout the study period. It evaluates patient adoption rates, market penetration, and the commercial performance of each therapy, providing a clear understanding of the factors driving or hindering the market acceptance of these treatments. The Therapeutics Assessment further highlights the Ovarian Cancer drugs, demonstrating the most rapid uptake. It examines the underlying drivers contributing to their swift adoption and compares the market share of these therapies to identify those gaining significant traction. Additionally, the report provides an in-depth overview of the current therapeutic pipeline for Ovarian Cancer, covering investigational drugs at various stages of development. It profiles the key pharmaceutical and biotech companies actively involved in advancing targeted treatments and presents the latest updates on partnerships, mergers and acquisitions, licensing deals, and other strategic developments shaping the future of Ovarian Cancer therapeutics. Ovarian Cancer Market Outlook The ovarian cancer treatment landscape is undergoing a significant transformation, with the integration of targeted therapies, personalized medicine, and ongoing clinical research aimed at improving long-term outcomes. High-grade serous ovarian cancer (HGSOC), the most prevalent subtype, continues to be treated with a combination of surgery and platinum-based chemotherapy. However, the emergence of maintenance therapies—especially PARP inhibitors—has reshaped post-treatment strategies for patients with BRCA or HRD mutations, helping reduce recurrence rates and extend progression-free survival. The future of ovarian cancer care is increasingly personalized, with clinical trials exploring novel options like immunotherapy, vaccine-based approaches, and radiation strategies for advanced or recurrent disease. These innovations reflect a broader trend toward therapies tailored to molecular profiles and disease stage, moving away from one-size-fits-all treatment. However, disparities in access to care remain a major challenge. Socioeconomic, racial, and geographic barriers often limit timely diagnosis and appropriate treatment, particularly in underserved populations. As awareness of BRCA testing and biomarker-driven treatment grows, expanding access to genetic screening and oncology expertise will be crucial. The ovarian cancer market is expected to expand steadily through 2034, driven by rising disease burden, evolving therapeutic options, and a growing emphasis on precision medicine. Addressing current gaps in care delivery, especially among high-risk and underserved groups, will be essential to unlocking the full potential of these medical advancements. Ovarian Cancer Market Drivers • The introduction of PARP inhibitors (e.g., olaparib, niraparib) and other targeted agents based on BRCA and HRD status has revolutionized ovarian cancer treatment, improving survival and reducing recurrence in select patient groups. • Increasing adoption of genetic and molecular testing for BRCA mutations, HRD status, and other biomarkers is enabling personalized treatment strategies, driving demand for advanced therapeutic options. Ovarian Cancer Market Barriers • The absence of reliable early screening methods and vague initial symptoms often lead to diagnosis at advanced stages, limiting curative treatment options and affecting patient outcomes. • Limited access to specialized oncology care, especially in rural and low-income regions, along with underutilization of genetic testing among minority populations, continues to hinder equitable treatment and diagnosis. Scope of the Ovarian Cancer Market Report • Study Period: 2020–2034 • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]. • Key Ovarian Cancer Companies: Genmab, AstraZeneca, On Target Laboratories, Chipscreen Biosciences, Aravive, Inc., Allarity Therapeutics, Merck KGaA, GlaxoSmithKline, Aprea Therapeutics, Verastem, Inc., Ellipses Pharma, Impact Therapeutics, Inc., BeiGene, Apexigen, Novartis Oncology, VBL Therapeutics, Cristal Therapeutics, Bayer, Regeneron Pharmaceuticals, DCPrime BV, AIM ImmunoTech Inc., Pharmicell Co., Ltd., Shattuck Labs, Inc., Laekna Limited, Celsion, and others. • Key Ovarian Cancer Therapies: Avutometinib + defactinib, Relacorilant, IMFINZI, Rinatabart sesutecan, Olvimulogene nanivacirepvec, Nemvaleukin alfa, Catequentinib, Raludotatug deruxtecan, Luveltamab Tazevibulin, Sacituzumab tirumotecan, Azenosertib (ZN-c3) + Niraparib, TORL-1-23, and others. • Ovarian Cancer Therapeutic Assessment: Ovarian Cancer currently marketed, and Ovarian Cancer emerging therapies. • Ovarian Cancer Market Dynamics: Ovarian Cancer market drivers and Ovarian Cancer market barriers. • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies. • Ovarian Cancer Unmet Needs, KOL's views, Analyst's views, Ovarian Cancer Market Access and Reimbursement. Table of Contents 1. Ovarian Cancer Market Report Introduction 2. Executive Summary for Ovarian Cancer 3. SWOT analysis of Ovarian Cancer 4. Ovarian Cancer Patient Share (%) Overview at a Glance 5. Ovarian Cancer Market Overview at a Glance 6. Ovarian Cancer Disease Background and Overview 7. Ovarian Cancer Epidemiology and Patient Population 8. Country-Specific Patient Population of Ovarian Cancer 9. Ovarian Cancer Current Treatment and Medical Practices 10. Ovarian Cancer Unmet Needs 11. Ovarian Cancer Emerging Therapies 12. Ovarian Cancer Market Outlook 13. Country-Wise Ovarian Cancer Market Analysis (2020–2034) 14. Ovarian Cancer Market Access and Reimbursement of Therapies 15. Ovarian Cancer Market Drivers 16. Ovarian Cancer Market Barriers 17. Ovarian Cancer Appendix 18. Ovarian Cancer Report Methodology 19. DelveInsight Capabilities 20. Disclaimer 21. About DelveInsight About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform, PharmDelve. Media Contact Company Name: DelveInsight Contact Person: Jatin Vimal Email: Send Email Phone: +14699457679 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: Nevada Country: United States Website:
Globe and Mail
18 hours ago
- Globe and Mail
2 No-Brainer Artificial Intelligence Stocks to Buy Right Now
No matter where you are on the artificial intelligence (AI) debate -- for or against -- there's no denying that it's transforming the way people work. Companies of all shapes and sizes are integrating into their daily workflows, and new industries are popping up because of it. The mass adoption of AI could result in a market size of more than $15 trillion by 2030, according to PwC research. Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Learn More » Fortunately, there are tons of AI companies out there that actually have a foothold in the market and aren't just flash-in-the-pan opportunities. Here are two well-established companies that are already benefiting from this trend and could be great AI stocks for years to come. 1. Taiwan Semiconductor Taiwan Semiconductor Manufacturing (NYSE: TSM) does exactly what its name describes -- it manufactures processors for companies. The world's leading chip designers, including Nvidia, rely on Taiwan Semiconductor (often referred to as TSMC) to make their processors because the company is so good at it. TSMC manufactures an estimated 90% of the world's artificial intelligence semiconductors, making it the clear leader in this market. This dominance led to TSMC's revenue rising 41% in the first quarter of 2025 to $25.5 billion and diluted earnings per share jumping 60% to $2.12 per American depository receipt (ADR). TSMC relies on its technological lead in semiconductor manufacturing to stay ahead of its competitors, and so far, it's still leading the pack. The company is focused on its 5-nanometer (nm) and 3nm chip production and management said recently that there continues to be "strong demand" for both. The company's CEO, C.C. Wei, said early this year he expects TSMC's artificial intelligence revenue to double this year compared to last year and recently reiterated that forecast. Taiwan Semiconductor stock has already gained 142% over the past three years, so what makes the stock a buy right now? Demand for semiconductors hasn't slowed down yet, and no one knows when or if it will. Companies are locked in an AI race right now, and a big part of that involves getting their hands on the most advanced AI chips. With TSMC's dominance in semiconducting manufacturing and it already holding a lead in advanced AI processors, the company is poised to benefit from chip demand as long as tech giants need the best processors available. And despite its share price gains, TSMC stock has a price to earnings ratio of just 25, which is below the P/E multiple of the broader S&P 500. 2. Microsoft Microsoft (NASDAQ: MSFT) has made itself an important player in artificial intelligence by making strategic investments in ChatGPT creator OpenAI over the past several years. The early move gave Microsoft access to one of the most advanced AI chatbots on the market, and it quickly implemented ChatGPT into everything from its Microsoft 365 suite of productivity tools to its GitHub Copilot coding assistant. That's helped Microsoft stay relevant in a rapidly shifting tech market and benefit from AI's growth. Part of Microsoft's AI strategy has been to offer more advanced services with its Azure cloud computing platform, which has helped result in a 35% jump in cloud services sales in the fiscal third quarter (which ended March 31). Microsoft is the second-largest public cloud computing provider with 21% market share, trailing only Amazon, which holds 30%. Microsoft has narrowed this gap over the past few years, and its investments in artificial intelligence infrastructure could make it an even stronger contender. The company will spend $80 billion on cloud infrastructure this fiscal year alone to stay ahead of the competition. Microsoft's stock is a bit more expensive than Taiwan Semiconductor's, with a P/E multiple of 36. But with Microsoft already off to a strong start in implementing advanced AI into its software and benefiting from AI cloud services, the company is setting itself up to remain a leading tech player for years to come. Should you invest $1,000 in Taiwan Semiconductor Manufacturing right now? Before you buy stock in Taiwan Semiconductor Manufacturing, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Taiwan Semiconductor Manufacturing wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $659,171!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $891,722!* Now, it's worth noting Stock Advisor 's total average return is995% — a market-crushing outperformance compared to172%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of June 9, 2025 John Mackey, former CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool's board of directors. Chris Neiger has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Amazon, Microsoft, Nvidia, and Taiwan Semiconductor Manufacturing. The Motley Fool recommends the following options: long January 2026 $395 calls on Microsoft and short January 2026 $405 calls on Microsoft. The Motley Fool has a disclosure policy.
